Orthocell Ltd (ASX: OCC) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Orthocell Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Orthocell Ltd (ASX: OCC)
Latest News
Healthcare Shares
Orthocell (ASX:OCC) share price surges 13% on study success
Healthcare Shares
Why the Orthocell (ASX:OCC) share price is flying higher today
Healthcare Shares
Here's why the Orthocell (ASX:OCC) share price is on the move today
Healthcare Shares
The Orthocell (ASX:OCC) share price is on the rise today. Here's why
Share Market News
Why the Orthocell (ASX:OCC) share price is edging higher today
Share Market News
Why is the Orthocell (ASX:OCC) share price falling today?
Share Market News
Why the Orthocell (ASX:OCC) share price is on the rise
Share Market News
Why the Orthocell (ASX:OCC) share price is rocketing 23% higher
Share Market News
Why the Orthocell (ASX:OCC) share price has popped 6% today
Share Market News
Why the Orthocell (ASX:OCC) share price is edging higher today
Share Market News
Orthocell (ASX:OCC) share price jumps 17% on positive clinical trials
Share Market News
The Orthocell share price is going nuts on claims of a blockbuster medical breakthrough
OCC ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
---|---|---|---|---|---|
YesNo |
About Orthocell Ltd
Orthocell Ltd is a regenerative medicine company. The company is engaged in the development and commercialization of biological medical devices, cell therapies, and related technologies to address unmet clinical needs in human health in the regenerative medicine industry. Its product includes Striate plus; Remplir which is a collagen wrap used in peripheral nerve repair; and OrthoACI an implantation used for the treatment of articular cartilage defects in the knee and ankle. It also has various other products in its pipeline such as Tendon Cell Therapy and Collagen Medical Device Platform.
OCC Share Price History Data provided by Morningstar.
Date | Close | Change | % Change | Volume | Open | High | Low |
---|---|---|---|---|---|---|---|
01 Nov 2024 | $0.61 | $-0.01 | -1.61% | 1,913,148 | $0.63 | $0.63 | $0.61 |
31 Oct 2024 | $0.62 | $0.00 | 0.00% | 1,108,360 | $0.62 | $0.64 | $0.62 |
30 Oct 2024 | $0.62 | $-0.03 | -4.65% | 830,467 | $0.65 | $0.65 | $0.62 |
29 Oct 2024 | $0.65 | $0.00 | 0.00% | 381,124 | $0.65 | $0.65 | $0.63 |
28 Oct 2024 | $0.65 | $-0.04 | -5.84% | 935,689 | $0.69 | $0.69 | $0.64 |
25 Oct 2024 | $0.69 | $0.00 | 0.00% | 1,324,139 | $0.64 | $0.69 | $0.62 |
23 Oct 2024 | $0.69 | $-0.04 | -5.52% | 731,108 | $0.71 | $0.72 | $0.67 |
22 Oct 2024 | $0.73 | $0.05 | 7.41% | 1,122,822 | $0.69 | $0.75 | $0.68 |
21 Oct 2024 | $0.68 | $0.02 | 3.03% | 529,952 | $0.66 | $0.71 | $0.66 |
18 Oct 2024 | $0.66 | $0.00 | 0.00% | 421,910 | $0.67 | $0.67 | $0.65 |
17 Oct 2024 | $0.66 | $-0.05 | -7.04% | 1,006,377 | $0.69 | $0.69 | $0.65 |
16 Oct 2024 | $0.71 | $-0.02 | -2.74% | 1,249,455 | $0.72 | $0.74 | $0.68 |
15 Oct 2024 | $0.73 | $0.10 | 15.75% | 1,510,085 | $0.64 | $0.73 | $0.63 |
14 Oct 2024 | $0.64 | $-0.03 | -4.55% | 1,734,322 | $0.68 | $0.70 | $0.61 |
11 Oct 2024 | $0.66 | $-0.01 | -1.50% | 3,773,497 | $0.68 | $0.77 | $0.65 |
10 Oct 2024 | $0.67 | $0.12 | 21.82% | 3,169,316 | $0.57 | $0.68 | $0.57 |
09 Oct 2024 | $0.55 | $0.04 | 7.77% | 1,568,541 | $0.53 | $0.55 | $0.53 |
08 Oct 2024 | $0.52 | $0.04 | 8.33% | 2,593,557 | $0.51 | $0.53 | $0.50 |
07 Oct 2024 | $0.48 | $0.02 | 4.35% | 688,340 | $0.47 | $0.49 | $0.47 |
04 Oct 2024 | $0.46 | $0.01 | 2.20% | 189,527 | $0.46 | $0.47 | $0.46 |
03 Oct 2024 | $0.46 | $0.05 | 12.20% | 653,009 | $0.42 | $0.46 | $0.41 |
Director Transactions Data provided by Morningstar.
Date | Director | Type | Amount | Value | Notes |
---|---|---|---|---|---|
15 Oct 2024 | Paul Anderson | Buy | 80,426 | $58,710 |
Exercise of options.
|
15 Oct 2024 | Paul Anderson | Exercise | 5,200,000 | $3,796,000 |
Exercise of options. Cashless exercise of Unlisted Options.
|
15 Oct 2024 | Paul Anderson | Buy | 268,089 | $195,704 |
Exercise of options. Cashless exercise of Unlisted Options.
|
24 Apr 2024 | John Wielen | Buy | 20,000 | $7,622 |
On-market trade.
|
15 Apr 2024 | John Wielen | Buy | 35,000 | $13,646 |
On-market trade.
|
17 Jan 2024 | Kim Beazley AC | Issued | 2,000,000 | $820,000 |
Issue of options.
|
20 Nov 2023 | Fiona Wood | Issued | 2,000,000 | $820,000 |
Issue of options.
|
15 Nov 2023 | John Wielen | Issued | 250,000 | $91,250 |
Issue of securities.
|
07 Nov 2023 | Paul Anderson | Issued | 500,000 | $192,500 |
Issue of options.
|
Directors & Management Data provided by Morningstar.
Name | Title | Start Date | Profile |
---|---|---|---|
Professor Fiona Melanie Wood | Non-Executive Director | Nov 2023 |
Professor Wood has over 30 years of experience as a plastic and reconstructive surgeon. Professor Wood is currently a Consultant Plastic Surgeon at Fiona Stanley Hospital and Perth Children's Hospital, and the Winthrop Professor of Surgery at the University of Western Australia.
|
Mr Paul Frederick Anderson | Managing Director | Mar 2006 |
Mr Anderson has over 20 years of experience in the medical device and regenerative medicine fields with expertise in bridging the gap between research and clinical practice in the development of emerging medical technologies. He also has expertise in the establishment of GMP manufacturing facilities and scale-up activities for cell therapies and biological medical devices, and the associated regulatory filings.
|
Dr Ravi Thadhani | Non-Executive Director | Mar 2023 |
Dr Thadhani is an Independent Non-Executive director of Orthocell who has co-authored more than 300 scientific publications, including articles in medical journals. Dr Thadhani has more than 30 years as a general and specialised physician, researcher, medical administrator and commercialisation adviser and has experience in patient care, advancing novel research programs, US regulatory pathways and commercialisation of devices and therapeutics. Dr Thadhani has served on multiple US FDA advisory committees in the musculoskeletal, cardiovascular and renal sectors and has acted as expert advisor to multiple global pharmaceutical companies including Sandoz, Shore, Novartis, Celgene, Bayer and Reata on clinical trial design, execution and data monitoring.
|
Mr John Van Der Wielen | Non-Executive ChairmanNon-Executive Director | Jun 2023 |
Mr Wielen has over 30 years in wealth management, private banking, investments, and insurance, which includes executive positions in global financial services groups. These positions allowed Wielen to work in London, Luxemburg, Malaysia, Sydney and Perth, for brands such as Crown Resorts, Blackstone, HBF Health Ltd, Lloyds Banking Group, Lombard Assurance and ANZ Bank. Wielen currently holds the role of Chair, Crown Perth and is a Non-Executive Director on the Blackstone owned Crown Resorts Australia Ltd.
|
Hon Kim Beazley AC | Non-Executive Director | Jan 2024 |
Mr Beazley is an Independent Non-Executive director of Orthocell. Prior to this, Mr Beazley dedicated almost three decades to a career in Federal Parliament, representing the WA seats of Brand and Swan. Beazley held ministerial roles including Defence and Finance and served as Deputy Prime Minister and Leader of the Opposition. His parliamentary experience included committees on Intelligence, Foreign Affairs, Defence, and Trade.
|
Mr Peter Webse | Company Secretary | Mar 2023 |
-
|
Peter Webse | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
Name | Shares | Capital |
---|---|---|
Ming Hao Zheng & Fan Ying | 6,805,886 | 3.25% |
Mr Paul Frederick Anderson & Ms Nicole Jane Telford | 6,233,335 | 2.97% |
Mr Qixiao Zhou | 5,996,241 | 2.86% |
Mr Jia Xun Xu | 5,014,107 | 2.39% |
HSBC Custody Nominees (Australia) Limited | 4,420,632 | 2.11% |
Mr Patrick John McHale | 4,300,000 | 2.05% |
Wenola Pty Ltd | 3,609,058 | 1.72% |
Sankofa Strategic Equity Fund Limited | 2,462,000 | 1.17% |
Citicorp Nominees Pty Ltd | 2,448,297 | 1.17% |
The University of Western Australia | 2,360,973 | 1.13% |
Dr John Clifford Philpott & Mrs Rebecca Anne Philpott | 2,048,677 | 0.98% |
Sandini Pty Ltd | 1,784,911 | 0.85% |
Miss Kate Imogen Leaver | 1,698,762 | 0.81% |
Dr John Clifford Philpott | 1,560,216 | 0.74% |
Mr Tony Athas & Mrs Angela Athas | 1,430,000 | 0.68% |
Mr Vance Clark Moore | 1,360,000 | 0.65% |
Carjay Investments Pty Ltd | 1,351,352 | 0.64% |
Mr Bryan F Short | 1,300,000 | 0.64% |
Dr Russell Kay Hancock | 1,200,000 | 0.57% |
Aris Nominees Pty Ltd | 1,042,816 | 0.50% |